PMID- 37278601
OWN - NLM
STAT- MEDLINE
DCOM- 20230614
LR  - 20230614
IS  - 1607-8454 (Electronic)
IS  - 1024-5332 (Linking)
VI  - 28
IP  - 1
DP  - 2023 Dec
TI  - Efficacy and safety of an HDACi- and HMA-based protocol in adults with acute 
      myeloid leukemia of intermediate- and adverse-risk categories: a retrospective 
      study.
PG  - 2219930
LID - 10.1080/16078454.2023.2219930 [doi]
AB  - OBJECTIVE: Anthracyclines and cytarabine have comprised standard induction 
      therapy for acute myeloid leukemia (AML) for decades. Low overall survival of AML 
      is due to non-remission or relapse after remission. Hypomethylating agent (HMA) 
      decitabine combined with low-dose chemotherapy or other targeted agents has shown 
      promising effect for AML in clinical trials, especially in t(8;21) acute myeloid 
      leukemia. We previously investigated histone deacetylase inhibitor (HDACi) 
      chidamide could regulate Wnt/beta-catenin signaling pathway in leukemia cell lines. 
      METHODS: Adult patients with de novo or relapsed/refractory AML who were treated 
      with chidamide and decitabine in combination with chemotherapy (chidamide group, 
      n = 23) or only decitabine combination with chemotherapy (decitabine group, 
      n = 17) were analyzed. RESULTS: Chidamide group represented higher complete 
      response rate (82.6% and 52.9%, p = 0.0430, vs. decitabine group), 
      progression-free survival and overall survival rates (p = 0.0088 and p = 0.0139, 
      respectively), especially for patients with de novo AML. Hematological toxicity 
      and infections were the most common adverse events (AEs) in both groups, and they 
      were manageable by supportive treatments. CONCLUSIONS: This HDACi- and HMA-based 
      protocol is an effective and tolerable therapy for patients with AML. The 
      comprehensive mechanism and effects of chidamide in combination with decitabine 
      are worth to be further explored in AML.
FAU - Guo, Zhibo
AU  - Guo Z
AD  - Department of Hematology, The First Affiliated Hospital, Harbin Medical 
      University, Harbin, People's Republic of China.
FAU - Guo, Dan
AU  - Guo D
AD  - Department of Hematology, The First Affiliated Hospital, Harbin Medical 
      University, Harbin, People's Republic of China.
FAU - Kong, Desheng
AU  - Kong D
AD  - Department of Hematology, The Fourth Affiliated Hospital, Harbin Medical 
      University, Harbin, People's Republic of China.
FAU - Bian, Sicheng
AU  - Bian S
AD  - Department of Hematology, The First Affiliated Hospital, Harbin Medical 
      University, Harbin, People's Republic of China.
AD  - Institute of Hematology, The Second Hospital of Shanxi Medical University, 
      Taiyuan, People's Republic of China.
FAU - Lin, Leilei
AU  - Lin L
AD  - Department of Hematology, Yantai Yuhuangding Hospital, Qingdao University Medical 
      College, Yantai, People's Republic of China.
FAU - Fan, Shengjin
AU  - Fan S
AD  - Department of Hematology, The First Affiliated Hospital, Harbin Medical 
      University, Harbin, People's Republic of China.
FAU - Li, Qi
AU  - Li Q
AD  - Department of Hematology, The First Affiliated Hospital, Harbin Medical 
      University, Harbin, People's Republic of China.
FAU - Zhao, Yanqiu
AU  - Zhao Y
AD  - Department of Hematology, The First Affiliated Hospital, Harbin Medical 
      University, Harbin, People's Republic of China.
FAU - Jiang, Yanmeng
AU  - Jiang Y
AD  - Department of Hematology, The First Affiliated Hospital, Harbin Medical 
      University, Harbin, People's Republic of China.
FAU - Yan, Jiangrong
AU  - Yan J
AD  - Department of Hematology, The First Affiliated Hospital, Harbin Medical 
      University, Harbin, People's Republic of China.
FAU - Wang, Zheren
AU  - Wang Z
AD  - Department of Hematology, The First Affiliated Hospital, Harbin Medical 
      University, Harbin, People's Republic of China.
FAU - Sun, Lili
AU  - Sun L
AD  - Department of Hematology, The First Affiliated Hospital, Harbin Medical 
      University, Harbin, People's Republic of China.
FAU - Li, Yinghua
AU  - Li Y
AUID- ORCID: 0000-0002-8060-8221
AD  - Department of Hematology, The First Affiliated Hospital, Harbin Medical 
      University, Harbin, People's Republic of China.
LA  - eng
PT  - Journal Article
PL  - England
TA  - Hematology
JT  - Hematology (Amsterdam, Netherlands)
JID - 9708388
RN  - M801H13NRU (Azacitidine)
RN  - 04079A1RDZ (Cytarabine)
RN  - 776B62CQ27 (Decitabine)
RN  - 0 (Histone Deacetylase Inhibitors)
RN  - 87CIC980Y0 
      (N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide)
RN  - 0 (Antimetabolites, Antineoplastic)
SB  - IM
MH  - Adult
MH  - Humans
MH  - *Antineoplastic Combined Chemotherapy Protocols/adverse effects
MH  - *Azacitidine/adverse effects
MH  - Cytarabine/therapeutic use
MH  - Decitabine/adverse effects
MH  - *Histone Deacetylase Inhibitors/adverse effects
MH  - *Leukemia, Myeloid, Acute/metabolism
MH  - Retrospective Studies
MH  - *Antimetabolites, Antineoplastic/adverse effects
OTO - NOTNLM
OT  - Acute myeloid leukemia
OT  - HDACi
OT  - HMA
OT  - chemotherapy
OT  - chidamide
OT  - combination therapy
OT  - decitabine
EDAT- 2023/06/06 13:10
MHDA- 2023/06/08 06:42
CRDT- 2023/06/06 09:43
PHST- 2023/06/08 06:42 [medline]
PHST- 2023/06/06 13:10 [pubmed]
PHST- 2023/06/06 09:43 [entrez]
AID - 10.1080/16078454.2023.2219930 [doi]
PST - ppublish
SO  - Hematology. 2023 Dec;28(1):2219930. doi: 10.1080/16078454.2023.2219930.